Emerging Markets Holding Up As Takeda Pursues Turnaround
This article was originally published in PharmAsia News
Executive Summary
Takeda continues to insist that its generics-hit business is being successfully turned around on the back of strong growth for new drugs in gastroenterology and oncology, as well as in emerging markets, which combined now account for around half of group revenues.